Emily Menendez

GU Oncology Now

Limited data are available to guide the management of patients with clinically node-positive nonmetastatic bladder cancer (cN+ M0 BCa). <a href="https://ascopubs.org/doi/10.1200/JCO.23.00725" target="_blank" rel="noopener">Researchers from the United Kingdom carried out a multicenter, retrospective analysis</a> of survival outcomes in patients with node-positive disease to gain better insight.Several oncology centers that offered both bladder-sparing trimodal therapy (TMT) and radical cystectomy (RC) were utilized to collect data from patients diagnosed with cN+ M0 BCa. Overall survival (OS) and progression-free survival (PFS) outcomes were recorded, along with treatment details and clinical factors.The analysis included 287 patients with cN+ M0 BCa. The median OS was 1.55 years (95% CI, 1.35-1.82). Patients who received radical treatments (n=163), including RC (n=76) or radical dose radiotherapy (n=87) were associated with improved OS (hazard ratio [HR], 0.32; 95% CI, 0.23-0.44; P&lt;.001) compared with palliative treatment. The choice of radical treatment had no association with OS (HR, 0.94; 95% CI, 0.63-1.41; P=.76) or PFS (HR, 0.74; 95% CI, 0.50 to 1.08; P=.12) on multivariable analysis.Patients with cN+ m0 BCa had similar survival outcomes whether treated with surgery or radical therapy. As RC can result in poor morbidity for patients with an already poor survival rate, this research confirms that TMT should be a treatment option for patients with cN+ M0 BCa.

Bladder-Sparing Trimodal Therapy Improves OS Compared With Radical Therapy

Urothelial Carcinoma

As RC can result in poor morbidity, this research shows that TMT should be a treatment option for patients with cN+ M0 BCa.

Bladder-Sparing Trimodal Therapy Improves OS

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe